Cetifloxacin tablets, a class 3.1 new drug of Laimei pharmaceutical industry, obtained the approval of clinical trials

Laimei pharmaceutical announced in the evening of January 22 that the company had recently received the approval document and notice of approval opinions for clinical trials of drugs issued by the State Food and drug administration The cetifloxacin API and cetifloxacin tablets (50mg) declared by the company met the requirements for drug registration and agreed to conduct clinical trials Cetifloxacin tablets are the third class of chemicals It is understood that the first acceptance time of the above varieties is August 2011 The indications are applicable to laryngitis, tonsillitis, acute bronchitis and pneumonia caused by Staphylococcus, Streptococcus, pneumococcus and Enterococcus which are sensitive to the product Data show that sitafloxacin is a broad-spectrum quinolones antibacterial drug developed by Daiichi Sankyo Co., Ltd and used in clinic 50mg tablets and 10% fines were first marketed in Japan in January 2008 under the trade name gracevit At present, the drug is only listed in Japan, but not in China Laimei pharmaceutical said that the company will organize the implementation of clinical trials as soon as possible in accordance with the requirements of the national clinical trials After the completion of the relevant work, the company will report the relevant information to the State Food and drug administration The subsequent approval process required is to complete the clinical trials, apply for registration, technical review, and obtain approval or withdrawal according to the review opinions Qiu Yu, chairman and general manager of Laimei pharmaceutical, said at the shareholders' meeting held on the afternoon of the 21st that this year, on the one hand, the company will continue to adhere to the strategy of large varieties of medicine and continue to promote the bidding and promotion of new drugs such as Utilins and Esso; on the other hand, it will cultivate large health industries such as American ginseng and honey, which will become a new growth point of performance According to reports, after Utilins was officially listed in November last year, it went smoothly, among which Hunan Xiangtan sold more than 10000 pieces a month Next, bidding in Guangdong, Sichuan, Chongqing and other places will be carried out soon; American ginseng plans to sell 300-400 tons a year, with a total amount of 200-300 million yuan, with a gross profit rate of 25%.